Literature DB >> 23449391

p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway.

M Farhang Ghahremani1, S Goossens, D Nittner, X Bisteau, S Bartunkova, A Zwolinska, P Hulpiau, K Haigh, L Haenebalcke, B Drogat, A Jochemsen, P P Roger, J-C Marine, J J Haigh.   

Abstract

There is growing evidence that the p53 tumour suppressor downregulates vascular endothelial growth factor (VEGF) expression, although the underlying mechanisms remain unclear and controversial. Here we provide insights from in vitro experiments and in vivo xenotransplantation assays that highlight a dual role for p53 in regulating VEGF during hypoxia. Unexpectedly, and for the first time, we demonstrate that p53 rapidly induces VEGF transcription upon hypoxia exposure by binding, in an HIF-1α-dependent manner, to a highly conserved and functional p53-binding site within the VEGF promoter. However, during sustained hypoxia, p53 indirectly downregulates VEGF expression via the retinoblastoma (Rb) pathway in a p21-dependent manner, which is distinct from its role in cell-cycle regulation. Our findings have important implications for cancer therapy, especially for tumours that harbour wild-type TP53 and a dysfunctional Rb pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449391      PMCID: PMC3679451          DOI: 10.1038/cdd.2013.12

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  46 in total

Review 1.  VEGF receptor signalling - in control of vascular function.

Authors:  Anna-Karin Olsson; Anna Dimberg; Johan Kreuger; Lena Claesson-Welsh
Journal:  Nat Rev Mol Cell Biol       Date:  2006-05       Impact factor: 94.444

2.  Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription.

Authors:  Shuichi Ohkubo; Tomoaki Tanaka; Yoichi Taya; Kenji Kitazato; Carol Prives
Journal:  J Biol Chem       Date:  2006-04-19       Impact factor: 5.157

3.  Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.

Authors:  Gangjian Qin; Raj Kishore; Christine M Dolan; Marcy Silver; Andrea Wecker; Corinne N Luedemann; Tina Thorne; Allison Hanley; Cynthia Curry; Lindsay Heyd; Deepika Dinesh; Marianne Kearney; Fabio Martelli; Toshinori Murayama; David A Goukassian; Yan Zhu; Douglas W Losordo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

4.  Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.

Authors:  Veronica A Carroll; Margaret Ashcroft
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

5.  Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia.

Authors:  Anna-Liisa Nieminen; Suparna Qanungo; Elizabeth A Schneider; Bing-Hua Jiang; Faton H Agani
Journal:  J Cell Physiol       Date:  2005-08       Impact factor: 6.384

6.  Inactivation of the p53 pathway in retinoblastoma.

Authors:  Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer
Journal:  Nature       Date:  2006-11-02       Impact factor: 49.962

7.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

Authors:  Neta Erez; Morgan Truitt; Peter Olson; Sarah Tuttleton Arron; Douglas Hanahan
Journal:  Cancer Cell       Date:  2010-02-04       Impact factor: 31.743

8.  PEDF inhibits growth of retinoblastoma by anti-angiogenic activity.

Authors:  Huasheng Yang; Rui Cheng; Guoying Liu; Qinghua Zhong; Chaoyang Li; Weibin Cai; Zhonghan Yang; Jianxing Ma; Xia Yang; Guoquan Gao
Journal:  Cancer Sci       Date:  2009-08-27       Impact factor: 6.716

9.  Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.

Authors:  Sarah Francoz; Pascal Froment; Sven Bogaerts; Sarah De Clercq; Marion Maetens; Gilles Doumont; Eric Bellefroid; Jean-Christophe Marine
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 10.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

Authors:  Sonja Loges; Massimiliano Mazzone; Philipp Hohensinner; Peter Carmeliet
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  41 in total

1.  Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas.

Authors:  Garima Yagnik; Arman Jahangiri; Rebecca Chen; Jeffrey R Wagner; Manish K Aghi
Journal:  Mol Cell Endocrinol       Date:  2017-02-16       Impact factor: 4.102

2.  Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.

Authors:  Hui Tian; Nicole R Tackmann; Aiwen Jin; Junnian Zheng; Yanping Zhang
Journal:  J Biol Chem       Date:  2017-11-09       Impact factor: 5.157

3.  Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis.

Authors:  Haizhi Huang; Allen Y Chen; Yon Rojanasakul; Xingqian Ye; Gary O Rankin; Yi Charlie Chen
Journal:  J Funct Foods       Date:  2015-05-01       Impact factor: 4.451

4.  Extracellular vesicles derived from hypoxia-preconditioned olfactory mucosa mesenchymal stem cells enhance angiogenesis via miR-612.

Authors:  Lite Ge; Chengfeng Xun; Wenshui Li; Shengyu Jin; Zuo Liu; Yi Zhuo; Da Duan; Zhiping Hu; Ping Chen; Ming Lu
Journal:  J Nanobiotechnology       Date:  2021-11-21       Impact factor: 10.435

5.  TP53 mutational status is predictive of pazopanib response in advanced sarcomas.

Authors:  K Koehler; D Liebner; J L Chen
Journal:  Ann Oncol       Date:  2015-12-08       Impact factor: 32.976

6.  Loss of autocrine endothelial-derived VEGF significantly reduces hemangiosarcoma development in conditional p53-deficient mice.

Authors:  Morvarid Farhang Ghahremani; Enrico Radaelli; Katharina Haigh; Sonia Bartunkova; Lieven Haenebalcke; Jean-Christophe Marine; Steven Goossens; Jody J Haigh
Journal:  Cell Cycle       Date:  2014-03-11       Impact factor: 4.534

Review 7.  The p53 Transcriptional Network Influences Microglia Behavior and Neuroinflammation.

Authors:  Macarena S Aloi; Wei Su; Gwenn A Garden
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

8.  TAp63gamma is required for the late stages of myogenesis.

Authors:  S Cefalù; A M Lena; B Vojtesek; A Musarò; A Rossi; G Melino; E Candi
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.

Authors:  Richard J Kraus; Blue-Leaf A Cordes; Saraniya Sathiamoorthi; Parita Patel; Xueying Yuan; Tawin Iempridee; Xianming Yu; Denis L Lee; Paul F Lambert; Janet E Mertz
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

10.  Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.

Authors:  Qiaoling Sun; Jinghong Zhou; Zheng Zhang; Mingchuan Guo; Junqing Liang; Feng Zhou; Jingwen Long; Wei Zhang; Fang Yin; Huaqing Cai; Haibin Yang; Weihan Zhang; Yi Gu; Liang Ni; Yang Sai; Yumin Cui; Meifang Zhang; Minhua Hong; Junen Sun; Zheng Yang; Weiguo Qing; Weiguo Su; Yongxin Ren
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.